D Caimmi1,2, N Baiz2, L K Tanno1, P Demoly1,2, S Arnavielhe3, R Murray4, A Bedbrook5, K C Bergmann6,7, G De Vries8, W J Fokkens9, J Fonseca10,11, T Haahtela12, T Keil13,14, P Kuna15, J Mullol16, N Papadopoulos17,18, G Passalacqua19, B Samolinski20, P V Tomazic21, A Valiulis22, M van Eerd8, M Wickman23,24, I Annesi-Maesano2, J Bousquet5,25,26. 1. Allergy Unit, Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, CHRU de Montpellier, Montpellier, France. 2. Sorbonnes Universités, UPMC, UMR-S 1136, IPLESP, Equipe EPAR, Paris, France. 3. Kyomed, Montpellier, France. 4. Medical Communications Consultant, MedScript Ltd, Dundalk, Co Louth, Ireland. 5. MACVIA-France, Contre les Maladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France. 6. Comprehensive Allergy-Centre-Charité, Department of Dermatology and Allergy, Charité, Universitätsmedizin Berlin, Berlin, Germany. 7. Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany. 8. Peercode DV, Amsterdam, The Netherlands. 9. Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands. 10. Center for Health Technology and Services Research, CINTESIS, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. 11. Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal. 12. Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland. 13. Institute of Social Medicine, Epidemiology and Health Economics, Charité, Universitätsmedizin Berlin, Berlin, Germany. 14. Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany. 15. Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland. 16. Clinical & Experimental Respiratory Immunoallergy, ENT Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. 17. Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK. 18. Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital "P&A Kyriakou", University of Athens, Athens, Greece. 19. Allergy and Respiratory Diseases, IRCCS San Martino Hospital-IST-University of Genoa, Genoa, Italy. 20. Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland. 21. Department of ENT, Medical University of Graz, Graz, Austria. 22. Vilnius University Clinic of Children's Diseases and Public Health Institute, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium. 23. Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm. 24. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 25. INSERM, VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, U1168, Paris, France. 26. UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Paris, France.
Abstract
BACKGROUND: Visual Analogue Scale (VAS) is a validated tool to assess control in allergic rhinitis patients. OBJECTIVE: The aim of this study was to validate the use of VAS in the MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) app (Allergy Diary) on smartphones screens to evaluate allergic rhinitis symptoms and disease control. METHODS: Each user filled 4 different VAS measuring overall, nasal, ocular, and asthma symptoms at least once. Following COSMIN guidelines, we evaluated internal consistency, (Cronbach's alpha coefficient and test-retest), reliability (intraclass correlation coefficients), sensitivity, and acceptability of the MASK-Rhinitis VAS. RESULTS: Between 1 August 2015 and 31 July 2016, the app was used 14 612 times in 15 countries. A total of 1225 users used it more than once, during the evaluated period. The tool resulted to be statistically satisfactory, showing excellent internal consistency (Cronbach's test > 0.84, test-retest > 0.7), reliability (>0.9), and acceptability. In addition, the tool had a good sensitivity when users (n = 521) answered the VAS twice in less than 3 hours. CONCLUSIONS AND CLINICAL RELEVANCE: The MASK-rhinitis VAS is a reliable and valid tool to assess allergic control on smartphone screens, at the population level.
BACKGROUND: Visual Analogue Scale (VAS) is a validated tool to assess control in allergic rhinitispatients. OBJECTIVE: The aim of this study was to validate the use of VAS in the MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) app (Allergy Diary) on smartphones screens to evaluate allergic rhinitis symptoms and disease control. METHODS: Each user filled 4 different VAS measuring overall, nasal, ocular, and asthma symptoms at least once. Following COSMIN guidelines, we evaluated internal consistency, (Cronbach's alpha coefficient and test-retest), reliability (intraclass correlation coefficients), sensitivity, and acceptability of the MASK-Rhinitis VAS. RESULTS: Between 1 August 2015 and 31 July 2016, the app was used 14 612 times in 15 countries. A total of 1225 users used it more than once, during the evaluated period. The tool resulted to be statistically satisfactory, showing excellent internal consistency (Cronbach's test > 0.84, test-retest > 0.7), reliability (>0.9), and acceptability. In addition, the tool had a good sensitivity when users (n = 521) answered the VAS twice in less than 3 hours. CONCLUSIONS AND CLINICAL RELEVANCE: The MASK-rhinitis VAS is a reliable and valid tool to assess allergic control on smartphone screens, at the population level.
Authors: Jean Bousquet; Nhân Pham-Thi; Anna Bedbrook; Ioana Agache; Isabella Annesi-Maesano; Ignacio Ansotegui; Josep M Anto; Claus Bachert; Samuel Benveniste; Mike Bewick; Nils Billo; Sinthia Bosnic-Anticevich; Isabelle Bosse; Guy Brusselle; Moïses A Calderon; G Walter Canonica; Luis Caraballo; Victoria Cardona; Ana Maria Carriazo; Eugene Cash; Lorenzo Cecchi; Derek K Chu; Elaine Colgan; Elisio Costa; Alvaro A Cruz; Wienczyslawa Czarlewski; Stephen Durham; Motohiro Ebisawa; Marina Erhola; Jean-Luc Fauquert; Wytske J Fokkens; Joao A Fonseca; Nick Guldemond; Tomohisa Iinuma; Maddalena Illario; Ludger Klimek; Piotr Kuna; Violeta Kvedariene; Désirée Larenas-Linneman; Daniel Laune; Lan T T Le; Olga Lourenço; Joao O Malva; Gert Marien; Enrica Menditto; Joaquim Mullol; Lars Münter; Yoshitaka Okamoto; Gabrielle L Onorato; Nikos G Papadopoulos; Maritta Perala; Oliver Pfaar; Abigail Phillips; Jim Phillips; Hilary Pinnock; Fabienne Portejoie; Pablo Quinones-Delgado; Christine Rolland; Ulysse Rodts; Boleslaw Samolinski; Mario Sanchez-Borges; Holger J Schünemann; Mohamed Shamji; David Somekh; Alkis Togias; Sanna Toppila-Salmi; Ioanna Tsiligianni; Omar Usmani; Samantha Walker; Dana Wallace; Arunas Valiulis; Rianne Van der Kleij; Maria Teresa Ventura; Sian Williams; Arzu Yorgancioglu; Torsten Zuberbier Journal: J Thorac Dis Date: 2019-09 Impact factor: 2.895
Authors: Jakob Usemann; Binbin Xu; Edgar Delgado-Eckert; Insa Korten; Pinelopi Anagnostopoulou; Olga Gorlanova; Claudia Kuehni; Martin Röösli; Philipp Latzin; Urs Frey Journal: ERJ Open Res Date: 2018-11-20
Authors: João O Malva; Alda Amado; Alexandra Rodrigues; Anabela Mota-Pinto; Ana F Cardoso; Ana M Teixeira; Ana Todo-Bom; António Devesa; António F Ambrósio; António L Cunha; Bárbara Gomes; Carina Dantas; Cidalina Abreu; Isabel Santana; Jean Bousquet; João Apóstolo; Lúcia Santos; Lúcio Meneses de Almeida; Maddalena Illario; Rafaela Veríssimo; Vitor Rodrigues; Manuel T Veríssimo Journal: Front Med (Lausanne) Date: 2018-05-08
Authors: J Bousquet; S Arnavielhe; A Bedbrook; M Bewick; D Laune; E Mathieu-Dupas; R Murray; G L Onorato; J L Pépin; R Picard; F Portejoie; E Costa; J Fonseca; O Lourenço; M Morais-Almeida; A Todo-Bom; A A Cruz; J da Silva; F S Serpa; M Illario; E Menditto; L Cecchi; R Monti; L Napoli; M T Ventura; G De Feo; D Larenas-Linnemann; M Fuentes Perez; Y R Huerta Villabolos; D Rivero-Yeverino; E Rodriguez-Zagal; F Amat; I Annesi-Maesano; I Bosse; P Demoly; P Devillier; J F Fontaine; J Just; T P Kuna; B Samolinski; A Valiulis; R Emuzyte; V Kvedariene; D Ryan; A Sheikh; P Schmidt-Grendelmeier; L Klimek; O Pfaar; K C Bergmann; R Mösges; T Zuberbier; R E Roller-Wirnsberger; P Tomazic; W J Fokkens; N H Chavannes; S Reitsma; J M Anto; V Cardona; T Dedeu; J Mullol; T Haahtela; J Salimäki; S Toppila-Salmi; E Valovirta; B Gemicioğlu; A Yorgancioglu; N Papadopoulos; E P Prokopakis; S Bosnic-Anticevich; R O'Hehir; J C Ivancevich; H Neffen; E Zernotti; I Kull; E Melen; M Wickman; C Bachert; P Hellings; S Palkonen; C Bindslev-Jensen; E Eller; S Waserman; M Sova; G De Vries; M van Eerd; I Agache; T Casale; M Dykewickz; R N Naclerio; Y Okamoto; D V Wallace Journal: Clin Transl Allergy Date: 2018-10-25 Impact factor: 5.871